AGIO:NASDAQ
Agios Pharmaceuticals Inc
28,72 USD
arrow_downward
-0,12%(-0,035) 1D
20-ноя., 09:37:43 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
High
28,92 USD
Low
27,87 USD
Mkt. cap
1,72 млд
Avg. vol.
1,13 млн
Volume
10,00
52-wk high
44,09 USD
52-wk low
23,00 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
High
28,92 USD
Low
27,87 USD
Mkt. cap
1,72 млд
Avg. vol.
1,13 млн
Volume
10,00
52-wk high
44,09 USD
52-wk low
23,00 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Reuters
·
31 мүнөт мурун
SocGen sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
43 мүнөт мурун
Ryan Detrick: S&P 500 posts six-day losing streak, longest since April 2024
Bloomberg.com
·
1 саат мурун
S&P 500 Faces Technical Make-or-Break Moment Below 7,200 Line
Barron's
·
2 саат мурун
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc